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BACKGROUND: Cytoglobin (Cygb) was first described in 2002 as an intracellular globin of unknown function. We have previously
shown the downregulation of cytoglobin as a key event in a familial cancer syndrome of the upper aerodigestive tract.
METHOD: Cytoglobin expression and promoter methylation were investigated in sporadic head and neck squamous cell carcinoma
(HNSCC) using a cross-section of clinical samples. Additionally, the putative mechanisms of Cygb expression in cancer were explored
by subjecting HNSCC cell lines to hypoxic culture conditions and 5-aza-2-deoxycitidine treatment.
RESULTS: In clinically derived HNSCC samples, CYGB mRNA expression showed a striking correlation with tumour hypoxia
(measured by HIF1A mRNA expression P¼0.013) and consistent associations with histopathological measures of tumour
aggression. CYGB expression also showed a marked negative correlation with promoter methylation (P¼0.018). In the HNSCC cell
lines cultured under hypoxic conditions, a trend of increasing expression of both CYGB and HIF1A with progressive hypoxia was
observed. Treatment with 5-aza-2-deoxycitidine dramatically increased CYGB expression in those cell lines with greater baseline
promoter methylation.
CONCLUSION: We conclude that the CYGB gene is regulated by both promoter methylation and tumour hypoxia in HNSCC and that
increased expression of this gene correlates with clincopathological measures of a tumour’s biological aggression.
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Cytoglobin (CYGB) is a candidate tumour-suppressor gene on
chromosome 17q25 and is the only gene completely contained
within the 42.5-kb Tylosis with Oesophageal Cancer (TOC)
minimal region (Langan et al, 2004). CYGB is a recently described,
intracellular globin (Burmester et al, 2002, 2004) whose function
was, until recently, unknown (Trent III and Hargrove, 2002).
Phylogenetic principles suggest that it has a common ancestral
origin with vertebrate myoglobins (Hankeln et al, 2005). TOC is a
rare, autosomal dominantly inherited skin condition associated
with an increased risk of squamous cell oesophageal cancer and
oral lesions (Tyldesley, 1974; Ellis et al, 1994). The 17q25 TOC
minimal region is subject to frequent allelic imbalance in sporadic
oesophageal cancer and CYGB is dramatically downregulated in
affected (non-malignant) tylotic oesophageal tissue compared with
normal oesophagus (McRonald et al, 2006). The mechanism of
downregulation of CYGB in TOC is unclear, as no mutations have
been identified in affected tissue (Shahabi et al, 2004), although
there is evidence that CYGB promoter methylation may occur in
sporadic oesophageal cancer (McRonald et al, 2006) and possibly
also in ovarian cancer (Presneau et al, 2005).
Our recent study of CYGB promoter methylation in head and
neck squamous cell carcinoma (HNSCC) using quantitative
pyrosequencing methylation analysis (PMA) shows that methyla-
tion is both common (65% of cases) and significantly tumour-
specific (P¼0.02) in cancers at this site (Shaw et al, 2006).
Furthermore, CYGB expression has recently been shown by us to
be significantly downregulated in 54% sporadic non-small cell lung
cancer (NSCLC) in comparison with surrounding ‘normal’ tissues
(Xinarianos et al, 2006). The potential utility of CYGB promoter
methylation as a molecular biomarker in NSCLC (Shivapurkar
et al, 2008) and HNSCC (Shaw et al, 2007) has also been explored.
Tumour suppressor activity of CYGB has recently been shown in
NSCLC and breast cancer cell lines (Shivapurkar et al, 2008).
Exactly what function the Cygb protein may have in aerodigestive
tract squamous malignancy has not yet been elucidated.
The exact physiological role of Cygb is currently speculative,
although intracellular oxygen storage, peroxidase function, oxygen
sensing or binding and detoxification of nitric oxide have all been
suggested (Burmester et al, 2002, 2004; Trent III and Hargrove,
2002; Hankeln et al, 2005; Hodges et al, 2008). It has been recently
shown that upregulation of CYGB in rat liver cells has a protective Received 25 February 2009; revised 7 May 2009; accepted 11 May 2009
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seffect against damage-induced fibrosis (Xu et al, 2006) and this has
led to the hypothesis that CYGB has a homoeostatic effect,
inhibiting free radical-induced fibroblast activation and conse-
quent fibrosis. Hyperplasia of tissues resulting from downregula-
tion of CYGB might conceivably constitute the first step in
malignant transformation, although this suggested mechanism is
speculative.
The role of Cygb in the cellular response to hypoxia may also be
of significance in established malignancy. Initial speculation on the
function of Cygb in hypoxia was generated not only from its
structural similarity to oxygen transport molecules, but also from
its localisation in areas of poor vascularity such as the brain and
retina (Ostojic et al, 2006; Li et al, 2007). Subsequent studies on
hippocampal cell lines confirmed that hypoxia upregulates CYGB
mRNA expression in a ‘dose-dependent’ manner (Fordel et al,
2004a,b). Further work on HIF1A (þ/1) knockout mice confirmed
that this effect is mediated by the HIF1A pathway and also that the
CYGB gene contains hypoxia responsive elements and mRNA
stabilisation sites (Fordel et al, 2004a). Hypoxia is a known
endogenous marker of poor prognosis in HNSCC. In particular it
seems to be related to resistance to radiotherapy (Koukourakis
et al, 2006) and chemotherapy. The cellular response to hypoxia
seems to be mediated by HIF1A in malignancy (Maxwell, 2005)
and has been extensively studied in HNSCC (Brennan et al, 2005;
Quintero et al, 2006).
In the current study, we measured CYGB gene expression and
promoter methylation in a series of head and neck cancer tumours
and determined associations with histopathology, clinical char-
acteristics and established markers of tumour hypoxia such as
HIF1A expression and tumour thickness. We also investigated the
CYGB and HIF1A response of human oral tumour cell lines to
hypoxic conditions.
MATERIALS AND METHODS
Patient cohort and tissue procurement
Tumour samples (5mm
3) were taken at the time of operation from
37 patients with biopsy-proven oral or oropharyngeal squamous
cell carcinoma and snap frozen in liquid N2. Surgical margin
samples were collected from seven of these patients at the same
time for use as ‘normal’ (i.e. histologically tumour-free) samples.
Selection criteria included the intention to treat by primary
surgery and the absence of previous similar malignancy or
treatment. Detailed tumour and patient characteristics were
documented, including clinical and pathological TNM staging.
The human tissue that formed the basis for this research was
collected under ethical approvals (Central Liverpool) LREC 07/Q1505/
1 5( 7M a r c h2 0 0 7 )a n d( S o u t hS e f t o n )E C . 4 7 . 0 1( 1J u l y2 0 0 2a m e n d e d
on 1 March 2006) and patients gave informed consent in all cases.
Sample preparation
DNA was extracted from 2-mm
3 frozen tissue using DNeasy
(Qiagen Ltd, Crawley, West Sussex, UK). Bisulphite treatment of
2mg of each DNA sample was undertaken using the EZ DNA
Methylation Kit (Zymo Research Corporation, Orange, CA, USA)
before methylation analysis.
RNA was prepared from additional 2-mm
3 frozen tissue
specimens using RNeasy (Qiagen Ltd). Adequate RNA quality
and concentration was confirmed using RNA Labchip with a 2100
Bioanalyser (Agilent Technologies Inc, Santa Clara, CA, USA).
cDNA was prepared from 1–2mg of RNA using RETROscript two-
step reverse transcriptase PCR with random decamers (Ambion,
Applied Biosystems, Warrington, UK). The quality of resultant
cDNA and absence of contamination was confirmed by PCR using
b-actin primers.
Positive and negative controls were prepared from human cell
lines known to be 100% methylated (CRL5935) and 100%
unmethylated (HNBE) at the CYGB promoter.
Quantitative pyrosequencing methylation analysis
Pyrosequencing methylation analysis was carried out as previously
described (Shaw et al, 2006). Briefly, hot start PCR was carried out
using 100ng of bisulphite-treated DNA template. Pyrosequencing
was carried out using the PSQ96MA System (Biotage, Qiagen Ltd)
according to manufacturer’s protocol, including single strand-
binding protein (PyroGold reagents, Qiagen Ltd). An average
methylation index (MtI) was calculated from the mean of the four
CpG sites evaluated as previously described.
Real-time mRNA expression assays
Real-time PCR reactions were carried out using the relative
quantification software supplied with the Applied Biosystems 7500.
The target genes were CYGB and HIF1A, using FAM/MGB-labelled
Taqman probes (Hs00370478_m1 and Hs00153153_m1, respec-
tively; Applied Biosystems). The endogenous control ‘house-
keeping gene’ was TATA-box-binding protein (Hs99999910_m1),
as this was less likely to be affected by hypoxia than other possible
control genes (Jogi et al, 2004; Fink et al, 2008). Each reaction
was carried out in duplicate and the mean result was used. Relative
gene expression was calculated using the 2
 DDC
T method (Livak and
Schmittgen, 2001). The values for each tumour-derived sample
were subsequently normalised relative to the mean of the seven
histologically tumour-free epithelial samples taken from the limits
of surgical resections.
HIF1A immunohistochemistry
FFPE tumour blocks were available in 32 of the clinical cases and
presence of carcinoma was confirmed. Immunohistochemical
detection of HIF1A was performed using the Tyramide Signal
Amplification System (NEN Life sciences, Boston, MA, USA).
Sections of 4-mm thickness were deparaffinized and the antigen
was retrieved by microwaving in 10mmoll
 1 citrate buffer (ph 6.0)
for 25min followed by blocking steps according to the manufac-
turer’s protocol and overnight incubation at 41C with 1:100
dilution of mouse monoclonal antibody 610958 (BD Biosciences,
Oxford, UK). After application of the secondary antibody,
biotinylated rabbit anti-mouse (DakoCytomation, Ely, UK), the
antigen was visualised using diaminobenzidine (DakoCytomation)
and the sections were counterstained with haematoxylin, dehy-
drated and mounted. Substitution of the primary antibody with the
identical concentration of mouse immunoglobulin IgG1 (Dako-
Cytomation) served as a negative control. The scoring system was
as follows: 0, no nuclear staining; 1, o10% nuclear staining; 2,
10–29% nuclear staining and 3, 430% nuclear staining. The
scoring system has been validated and used in other studies of
HNSCC (Silva et al, 2008).
Cell lines
Six human HNSCC cell lines (PE/CA-PJ15, PE/CA-PJ41, bhy, hn,
jh012, jh019) and HeLa were subject to low ambient oxygen
concentrations as follows. Cells were cultured in 5% CO2, 20% O2,
75% N2 at 371C in RPMI-1640 supplemented with newborn calf
serum (10%) and L-glutamine (1%) and sub-cultured using
trypsin-EDTA. For each cell line, three 75-cm
2 flasks were cultured
until 50% confluence was achieved. The first flask of each cell line
constituted the experimental control. The second flask was subject
to anoxia (0% O2, 10% CO2, 10% H2, 80% N2) for 6h and the third
was cultured under anoxic conditions for 24h. Immediately after
completion of the timed incubations, the cells were harvested and
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sDNA and RNA were extracted simultaneously (Allprep DNA/RNA
Mini Kit (Qiagen Ltd)). CYGB methylation data and CYGB and
HIF1A mRNA expression data were derived as above. Cell lines
were cultured on three separate occasions to undertake the
experiments in triplicate.
RESULTS
The range of pathological staging in this series of 37 tumours
seemed to be typical of our practice. 35% (13) had cervical lymph
node metastases, 22% (8) with extracapsular involvement, 24% (9)
had frank mandibular invasion by tumour and 27% (10) had a
tumour thickness greater than 20mm. These features of biological
aggression were, as would be expected, interdependent, represent-
ing a subgroup of more aggressive tumours.
The MtI, a semi-quantitative measure of methylation for the
CYGB promoter in the tumour samples varied between 0.00 and
0.54 (mean 0.19). In total, 10 of the tumours had MtIo0.03 and 11
had MtI40.25. This distribution was consistent with our previous
report (Shaw et al, 2006) on a larger series of tumour and normal
samples. The finding in several other methylated genes that a
minimum threshold MtI of approximately 0.25 (i.e. 25% copies of
the gene methylated) was required to significantly downregulate
expression has been previously noted by our group (Shaw et al,
2008) and thus will be applied as a threshold in this analysis
The range of CYGB expression for tumour-free ‘normal’
epithelium was narrow (0.48–1.61). When normalised to the mean
from this ‘normal’ epithelium, a wide range of CYGB mRNA
expression was observed in tumours (0.14–10.7; mean 1.38). This
represents a 77-fold range in the expression of this gene in the
tumours. The data were considered in tertiles, with an under-
expressing group (p0.5 normal, n¼14), and an overexpressing
group (X1.5 normal, n¼11) being individually considered. The
control cell line with extensive CYGB promoter methylation
(CRL 5935, MtI 1.00) had very low levels of CYGB mRNA
expression (0.02) and the cell line without CYGB promoter
methylation (HNBE, MtI 0.00) showed relatively high levels of
expression (2.96). There was also a wide range of HIF1A mRNA
expression in the tumours (0.16–12.1; fold range 76; mean 1.70)
compared with ‘normal’ epithelium. The range for the normal
epithelium was again narrower (0.52–1.53).
Parameters affecting CYGB expression
All those samples with expression of CYGB mRNA X1.5 normal
had CYGB promoter MtI of o0.25 (Table 1). The data also show
that promoter methylation X0.25 was always associated with the
downregulation of CYGB. However, other cases had downregula-
tion apparently independent of promoter methylation. A clear
positive correlation between mRNA expression of CYGB and
HIF1A mRNA is shown in Figure 1 (Po0.01). As may be expected,
there was no correlation between HIF1A expression and CYGB MtI
(Spearman’s rho  0.10, P¼0.58). However, those tumours with
relatively lower levels of CYGB promoter methylation (MtIX0.25)
showed stronger correlation between expression of CYGB and
HIF1A expression (Table 1).
Borderline significant correlations were observed between CYGB
expression and clinicopathological features of biological aggres-
sion. Overexpression of CYGB (X1.5 normal) was associated
with extracapsular tumour spread in cervical lymph nodes (63%
(5 out of 8) vs 21% (6 out of 28), P¼0.04, Fisher’s exact), greater
depth of invasion X20mm (46% (6 out of 13) vs 22% (5 out of 23),
P¼0.15, Fishers exact), the presence of cervical lymph node
metastases (46% (6 out of 13) vs 22% (5 out of 23), P¼0.15,
Fisher’s exact), the presence of mandibular invasion by tumour
(56% (5 out of 9) vs 22% (6 out of 27), P¼0.10, Fisher’s exact) and
an Anneroth score X19 (47% (7 out of 15) vs 13% (2 out of 15),
P¼0.10, Fisher’s exact). No significant correlation with survival or
recurrence was found, although there were only five such events
in this series of 37 patients and the effect of prescription bias (e.g.
confounding survival benefit of post-operative chemoradiation in
the most aggressive tumours) must be considered. There was one
markedly aggressive tumour (20-mm depth of invasion and 11
positive lymph nodes with extracapsular spread) with notably
reduced CYGB expression (p0.5 normal) This tumour showed
allelic imbalance at two markers close to CYGB on 17q25 (data not
Table 1 Interrelationship between CYGB methylation, CYGB expression and HIFA expression in HNSCC tissue samples
HIF1A expression
a
CYGB MtI CYGB expression
a o1 1.0–1.6 41.6
o0.25 p0.5 4 1 0 Spearman r¼0.62, P¼0.002
0.6–1.4 2 3 2
X1.5 1 2 8
X0.25 p0.5 5 2 1 Spearman r¼0.32, P¼0.32
0.6–1.4 1 2 1
X1.5 0 0 0
HNSCC¼head and neck squamous cell carcinoma; MtI¼methylation index.
aNormalised to the mean of expression in seven normal surgical margin samples (see Materials and
Methods).
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Figure 1 Correlation between CYGB mRNA expression and HIF1A
mRNA expression in head and neck squamous cell carcinoma (HNSCC)
tissue samples. (Spearman’s rho 0.558, Po0.01). Units on the x and y axes
are fold change normalised to the mean of seven normal margin tissue
samples (see Materials and Methods).
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sshown), thus offering a possible explanation for the reduced CYGB
expression independent of promoter methylation.
HIF1A immunohistochemistry and HIF1A mRNA expression for
the 32 individual tumours examined were positively correlated,
although the significance was borderline (Spearman’s rho 0.325,
P¼0.07). The samples with the highest HIFA1 staining (n¼6; all
430%) had significantly greater HIFA1 mRNA expression (mean
4.48) compared with the less hypoxic samples (n¼26; mean 1.04)
(Kruskall–Wallis, P¼0.001). In the samples with CYGB MtIo0.25,
the correlation between CYGB mRNA expression and HIFA1
immunohistochemistry scoring was near significant (Kruskall–
Wallis, P¼0.07), but there was no appreciable trend in the cases
with higher values of CYGB methylation.
Human SCCHN cell lines and HeLa
The hn cell line had no detectable CYGB promoter methylation
(MtI 0.0), bhy and HeLa had intermediate levels of methylation
(MtI 0.75 and 0.67) and the remaining cell lines had near 100%
methylation (MtI 0.96–0.98). Methylation status was not affected
by either 6 or 24h of anoxic conditions in any of the cell lines (data
not shown).
All the seven cell lines showed an increase in HIF1A expression
(Figure 2) and a corresponding increase in CYGB expression
(Figure 3) with longer incubation under anoxic conditions. It
should be noted that the absolute levels of CYGB mRNA expression
(relative to hn) for the cell lines 012, 019 and PE/CA-PJ15 were
rather low, as were any incremental increases caused by hypoxia,
and that all these cell lines had MtI40.95. Consequently, the
relevance of such minute fluctuations in actual expression might
be questioned for these three cell lines. bhy, however, had higher
basal levels of CYGB expression despite an MtI40.75 and failed to
increase CYGB expression in response to hypoxia. Thus, the trend
was for increased CYGB expression with progressive hypoxia,
although the effect was reduced by high baseline CYGB expression.
Treatment of the hn, bhy and PE/CE-PJ15 cell lines (which
showed differing levels of CYGB promoter methylation and
baseline CYGB expression) with 5-aza-2-deoxycitidine to prevent
DNA methylation during DNA synthesis caused upregulation of
CYGB expression. The degree of upregulation seemed to be
dependent on the original level of promoter methylation and/or
the original level of CYGB expression (PE/CA-PJ41 upregulated
4350-fold, bhy upregulated two-fold; data not shown).
DISCUSSION
In the current study, we have measured CYGB gene expression and
promoter methylation in a series of head and neck tumours and
determined associations with histopathology, clinical character-
istics and established markers of tumour hypoxia such as HIF1A
expression and tumour thickness. We also investigated the CYGB
and HIF1A response of human oral cancer cell lines to hypoxic
conditions.
These experiments were performed on a modest series of
tumours. Although a multivariate analysis may seem attractive
(given the multifactorial hypothesis in question), this analysis
would prove underpowered with the data available. It was noted
that CYGB promoter methylation in the tumour samples never
rose above an MtI of 0.54, whereas the majority of the cell lines
(five out of six) showed much higher levels of methylation.
Correspondingly, high levels of methylation might be detected in
micro-dissected tumour tissue compared with our non-micro-
dissected specimens, as it is possible that different cell populations
in the tumour show different promoter methylation profiles, thus
advocating the use of laser capture microdissection and the
analysis of several different cell populations. Similarly, the range of
CYGB mRNA expression data from individual cell populations
might prove even greater that the current data show. There are,
however, some technical disadvantages to micro-dissection. The
total quantity of DNA obtained is much smaller and PMAs demand
relatively high quantity and quality of DNA, particularly as the
bisulphite treatment essential to the assay causes a degree of
fragmentation.
What remains uncertain is the exact role of the Cygb protein in
normal tissue, its level of expression in normal epithelium and
underlying stroma, and how this differs in malignancy. Our work
in this area has to date been hampered by the apparent lack of
specificity of currently available antibodies to the human Cygb
protein and its low level of basal expression in normal epithelial
cells (data not shown).
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Figure 2 Upregulation of HIF1A mRNA with hypoxia for six head and
neck squamous cell carcinoma (HNSCC) cell lines and HeLa. Expression is
shown relative to expression for each line in 21% O2. Unfilled bar,
normoxia; pale bar, 6h of hypoxia; dark bar, 24-h hypoxia. Bar charts
indicate mean of five samples with error bars±1 s.e.
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Figure 3 Upregulation of CYGB mRNA with hypoxia for six head and
neck squamous cell carcinoma (HNSCC) cell lines and HeLa. Corresponding
methylation data and expression data relative to the unmethylated HNSCC
cell line, hn, are shown below the figure. Expression is shown relative to
expression for each line in 21% O2. Unfilled bar, normoxia; pale bar, 6h of
hypoxia; dark bar, 24h hypoxia. Bar charts indicate mean of five samples
with error bars±1 s.e.
Hypoxic regulation of cytoglobin in HNSCC
RJ Shaw et al
142
British Journal of Cancer (2009) 101(1), 139–144 & 2009 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sOur initial work on promoter methylation found CYGB to be
significantly methylated in a tumour-specific pattern in around
65% of HNSCC (Shaw et al, 2006). This finding, and similar
findings in other aerodigestive tract cancers (Xinarianos et al,
2006) led us to believe that it has a role as a tumour suppressor
gene in HNSCC, perhaps by inhibiting free-radical or stress-
induced epithelial hyperplasia. However, the findings we describe
in this paper relating to tumour hypoxia and tumour behaviour
may seem to suggest that, in established malignancy, CYGB takes
on a role in relation to the response to tumour hypoxia. Notably,
we have observed a significant correlation between extracapsular
spread and overexpression of CYGB and consistent trends with
other prognostic markers, including depth of invasion and lymph
node involvement. However, no significant correlation with
disease-specific survival or recurrence was found, possibly due
to the small number of such events in this series of 37 patients and
the confounding survival benefit of post-operative chemoradiation
given to the most aggressive tumours.
Our observations lead us to conclude that both hypoxia and
promoter methylation influence CYGB expression. In the tissue
samples, the influence of tumour hypoxia seems greater when
CYGB promoter methylation is o50% of the maximal levels (i.e. at
an MtI of o0.25). However, all 12 of the tumours with CYGB
MtIX0.25 had relatively low levels of CYGB mRNA expression and
this was irrespective of significant variations in HIF1A expression.
Thus, assuming some heterogeneity of cell type in the tissue
samples examined, promoter methylation seems to have a
dominant effect on CYGB expression at values of MtI that may
represent complete or bi-allelic methylation of the gene (MtIX0.25
in this series). The HIFA1 immunohistochemistry data reinforce
the correlation seen at the mRNA level. This is significant because
regulation of HIF1A occurs by inhibition of degradation of the
subunit, as well as at the transcriptional level.
It may be proposed that mutation of the CYGB gene is of
importance in those tumours that show reduced expression of the
transcript but little or no promoter methylation. We have not
undertaken mutation screening of CYGB in the tumour samples in
this study, but we have previously sought, and failed to find, CYGB
mutations in sporadic oesophageal cancer specimens (McRonald
et al, 2006). Alternatively, other mechanisms of control could also
be proposed, such as histone deacetylation.
Interestingly, the levels of CYGB promoter methylation in all
seven of the cell lines investigated in the current study were
unchanged under culture conditions of reduced oxygen. Un-
expectedly, the PE/CA-PJ41 cell line showed an increase (approxi-
mately 10-fold) in CYGB expression under hypoxic conditions
despite an MtI 40.95. However, growth of PE/CA-PJ41 in the
presence of a DNA demethylating agent caused CYGB expression
to increase more than 350-fold, suggesting at least some role for
promoter methylation in this cell line. A trend of co-expression of
CYGB and HIF1A was observed in five of the seven cell lines
studied under hypoxic conditions. However, the absolute levels of
expression of CYGB were very low in three of the cell lines, which
had promoter methylation 40.95. These data imply that there may
be alternate control mechanisms for the activation of this gene and
may be explained by observations of hypoxia responsive mRNA
stabilisation sites in the gene (Fordel et al, 2004a). These trends
largely replicate in vitro our ex vivo cross-sectional tissue data and
lend further support to the role of tissue hypoxia in the regulation
of CYGB.
Hypoxia is a known endogenous marker of poor prognosis in
HNSCC and seems to be related to resistance to radiotherapy
(Koukourakis et al, 2006) and chemotherapy. This is reinforced in
our study in which correlations between hypoxia and biological
aggression of the tumours (such as depth of invasion, mandibular
invasion, involved cervical lymph nodes and extra-capsular
spread) were seen. The cellular response to hypoxia seems to be
mediated by HIF1A in malignancy (Maxwell, 2005) and has been
extensively studied in HNSCC (Brennan et al, 2005; Quintero et al,
2006). Should Cygb prove to be a critical component in the
hypoxia response, its manipulation might have therapeutic value,
particularly in response to radiation treatment. Is the over-
expression of CYGB necessary to mediate the hypoxia response, to
mediate VEGF expression (Fordel et al, 2004a), to subtend a
survival advantage in more aggressive tumours? Clearly more
studies are necessary to clarify exactly where CYGB fits in to the
cellular hypoxia story and whether it is up- or downstream of
HIF1A, currently viewed as the orchestrator of the tumour’s
response to hypoxia. The significance of such studies may not be
only in the field of basic science, as the modulation of HIF1A is
currently a focus for the development of novel radiosensitising
drugs. The ongoing controversy of the role of CYGB has been
recently highlighted by recent suggestions of its function as a
tumour suppressor gene in NSCLC (Shivapurkar et al, 2008) and
HNSCC (Shaw et al, 2006), and as a prospective gene therapy (Lv
et al, 2008) in the prevention of hepatocellular carcinoma after
liver cirrhosis.
In this work, we have shown the regulation of CYGB expression
in HNSCC by both promoter methylation and tumour hypoxia. We
have observed that clincopathological measures of a tumour’s
biological aggression are associated with overexpression of CYGB
and, in parallel, the overexpression of HIF1A. However, we have
also observed that, not only does substantial promoter methylation
have an overriding effect of CYGB downregulation irrespective of
hypoxia, but that CYGB upregulation in cell lines in response to
hypoxia may be less dependent on alterations in CYGB promoter
methylation status.
Statistical methods
The data were analysed using SPSS v15.0 software (SPSS Inc.,
Chicago, IL, USA).
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